Ulcerative Colitis | Disease Landscape and Forecast | G7 | 2020

The ulcerative colitis (UC) therapy market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz / Xeljanz XR) for moderate to severe disease, together with emerging agents with novel MOAs and a general increase in the use of targeted therapies, will drive market growth. In particular, the availability of non-TNF biologics (e.g., Takeda’s Entyvio, Janssen’s Stelara) and the oral Jak inhibitor Xeljanz / Xeljanz XR will expand physicians’ treatment armamentarium and intensify market competition. Offsetting this growth will be the continued generic erosion of conventional agents and the entry of and increased physician comfort prescribing less-expensive biosimilars, factors that will pose hurdles to the uptake of emerging therapies.

QUESTIONS ANSWERED

• What are the similarities and differences in the treatment of UC by U.S., European, and Japanese gastroenterologists?
• How do gastroenterologists perceive biosimilar agents, and what has been/will be their impact on the UC therapy market?
• What are KOLs’ insights into current treatment options (e.g., Pfizer’s Xeljanz / Xeljanz XR, Janssen’s Stelara)? What factors drive their treatment decisions?
• What are KOLs’ perceptions of key emerging therapies (e.g., AbbVie’s upadacitinib and risankizumab, Janssen’s guselkumab, Bristol Myers Squibb’s ozanimod, Arena’s etrasimod), and where do they see these agents fitting into the treatment algorithm?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.